Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of Heparin Starting Infusion Rate
NCT07250763Phase 4Active, not recruiting
- Sponsor
- Inova Health System
- Start
- Sep 2023
- Primary completion
- Feb 2027
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of heparin in deep vein thrombosis (DVT), pulmonary embolism (PE), Atrial fibrillation (AFib), acute coronary syndrome (ACS), mechanical heart valve, sponsored by Inova Health System. Started Sep 2023; status: active, not recruiting.
02
Drugs
heparin
03
Conditions
deep vein thrombosis (DVT)pulmonary embolism (PE)Atrial fibrillation (AFib)acute coronary syndrome (ACS)mechanical heart valve
Beyond the preview
Go deeper on NCT07250763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07250763.